Fennessy Fiona M, Mortele Koenraad J, Kluckert Thomas, Gogate Adheet, Ondategui-Parra Silvia, Ros Pablo, Silverman Stuart G
Department of Radiology, Division of Abdominal Imaging and Intervention, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
AJR Am J Roentgenol. 2004 Mar;182(3):651-5. doi: 10.2214/ajr.182.3.1820651.
We evaluated the prevalence and significance of hepatic capsular retraction in hepatic metastases from breast cancer and correlated these with metastatic number, size, change in size over time, breast tumor histopathology, chemotherapeutic regimen, and tumor-receptor status.
Abdominal CT scans of 200 consecutive women with breast carcinoma (mean age, 57 years; range, 33-81 years), obtained over a 7-month period, were retrospectively reviewed. Fifty-eight women had hepatic metastases. Two hundred seventy-two CT scans, including present and prior examinations (mean [+/- SD], 4.6 +/- 2 per patient), were evaluated. The number and diameter of liver metastases at all examinations, chemotherapeutic agents used, histopathologic diagnosis of breast tumor, and tumor-receptor status were compared in patients with and without capsular retraction. Descriptive analyses of the variables and comparisons of means and proportions as well as correlations were conducted.
Hepatic capsular retraction was observed in 29 patients with hepatic metastases (50%). Retraction ranged from 1 to 10 mm in depth. Patients with capsular retraction had significantly larger metastases than those without retraction (p < 0.05). The associations between retraction and increase in size of the subjacent metastasis and between retraction and decrease in size were statistically significant (p < 0.05). Capsular retraction was independent of the number of hepatic metastases, histopathologic diagnosis, tumor-receptor status, and chemotherapeutic regimen.
Hepatic capsular retraction is common in patients with hepatic metastases from breast cancer and is associated with larger metastases and both increase and decrease in subjacent lesion size. It is unrelated to lesion number, histopathology, receptor status, or chemotherapeutic regimen.
我们评估了乳腺癌肝转移中肝包膜回缩的发生率及其意义，并将这些与转移灶数量、大小、随时间的大小变化、乳腺肿瘤组织病理学、化疗方案及肿瘤受体状态进行关联分析。
回顾性分析了在7个月期间对200例连续的乳腺癌女性患者（平均年龄57岁；范围33 - 81岁）进行的腹部CT扫描。其中58例有肝转移。共评估了272次CT扫描，包括当前和既往检查（平均[±标准差]，每位患者4.6±2次）。比较了有和没有包膜回缩的患者在所有检查时肝转移灶的数量和直径、使用的化疗药物、乳腺肿瘤的组织病理学诊断以及肿瘤受体状态。对变量进行了描述性分析，并比较了均值、比例以及相关性。
在29例有肝转移的患者（50%）中观察到肝包膜回缩。回缩深度为1至10毫米。有包膜回缩的患者转移灶明显大于无回缩者（p < 0.05）。回缩与下方转移灶大小增加之间以及回缩与大小减小之间的关联具有统计学意义（p < 0.05）。包膜回缩与肝转移灶数量、组织病理学诊断、肿瘤受体状态及化疗方案无关。
肝包膜回缩在乳腺癌肝转移患者中很常见，并且与较大的转移灶以及下方病灶大小的增加和减小有关。它与病灶数量、组织病理学、受体状态或化疗方案无关。
